香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Zhong Jia Guo Xin Holdings Company Limited 中加國信控股股份有限公司 梁博士概無於本公司的股份或相關股份（定義見香港法例第 571 章證券及期貨條例（「 證券 及期貨條例」 ） 第 XV 部）中擁有任何權益。 （於百慕達註冊成立之有限公司） （股份代號：899） 1) 董事調職； 2) 委任獨立非執行董事；及 3) 董事會委員會組成變更 董事調職 中加國信控股股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董 事會」）欣然宣佈，其已批准梁金祥博士（「梁博士」）由獨立非執行董事調職為非執行董 事（「調職」），自 2026 年 1 月 23 日起生效。 梁博士的履歷詳情載列如下： 梁金祥博士，41 歲，於 2026 年 1 月 23 日獲委任為本公司非執行董事。梁博士長期專注于金融 及資本市場,擁有超過 16 年的投資與並購、企業風險控制及財務審計 ...

Summary of Key Points Core Viewpoint - The latest shareholder equity disclosures for several companies, including Zhongjia Guoxin, Boan Biotech, Fudan Zhangjiang, and others, were made on January 12, 2026, indicating significant changes in shareholdings among various institutional investors [1]. Group 1: Zhongjia Guoxin (00899) - Jiang Xiaojun increased holdings from 5.60 million shares to 16.80 million shares, representing a holding percentage of 3.77% [2] - Li Jiayi raised holdings from 23.39 million shares to 70.18 million shares, with a holding percentage of 15.76% [2] - Lin Bilin increased holdings from 0.10 million shares to 31.30 million shares, now holding 7.03% [2] - FULL TENDA DEVELOPMENT increased holdings from 23.88 million shares to 71.65 million shares, holding 16.09% [2] - GREEN DEER HOLDINGS LIMITED increased holdings from 0.10 million shares to 31.30 million shares, now holding 7.03% [2] - Yao Jigen increased holdings from 24.96 million shares to 74.88 million shares, with a holding percentage of 16.82% [2] Group 2: Boan Biotech (06955) - Yantai Green Leaf Pharmaceutical Holdings reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] - Luye Geneora Holding Limited acquired 50 million shares, holding 8.03% [2] - AsiaPharm Investments reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] - Shandong Green Leaf Pharmaceutical reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] - Luye Pharma Hong Kong Limited reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] Group 3: Other Companies - Fudan Zhangjiang (01349): Yang Zongmeng reduced holdings from 59.33 million shares to 55.79 million shares, now holding 7.85% [2] - Prosperity Industrial Trust (00778): ESR Asset Management increased holdings from 76.05 million shares to 80.57 million shares, now holding 3.92% [2] - Shishi Pharmaceutical Group (02005): Qu Jiguang maintained holdings at 1.233 billion shares, holding 41.79% [2] - Zheli Holdings (02209): Lei Baicheng slightly reduced holdings from 31.31 million shares to 31.05 million shares, now holding 7.43% [2]

Group 1 - The company, Zhongjia Guoxin (00899), announced a rights issue based on a "1 for 2" basis, issuing 297 million shares [1]

Group 1 - The company Zhongjia Guoxin (00899) announced a rights issue based on a "1 for 2" basis, issuing 297 million shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 中加國信控股股份有限公司 呈交日期： 2026年1月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 00899 | 說明 | 供股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份 ...

Core Viewpoint - The company announced the results of its rights issue, indicating a significant acceptance rate and the subsequent arrangements for the unallocated shares [1] Group 1: Rights Issue Results - The company received a total of 5 valid applications for the rights issue, amounting to 167 million shares, which represents approximately 56.39% of the total shares offered under the rights issue [1] - As a result of the valid acceptances, the total number of unallocated shares is 129 million [1] - The company has established a compensation arrangement through a placement agreement with a placement agent to facilitate the subscription of the unallocated shares [1] Group 2: Conditions and Issuance - All conditions related to the rights issue and placement have been fulfilled, making the rights issue and placement unconditional as of January 7, 2026 [1] - The total number of shares to be allotted and issued will be 297 million, which accounts for 100% of the shares offered for subscription under the rights issue [1]

Core Viewpoint - 中加国信 has successfully received valid applications for a total of 167 million shares in its rights issue, representing approximately 56.39% of the total shares offered [1] Group 1: Rights Issue Details - The company received a total of 5 valid applications for the rights issue by the deadline of December 17, 2025 [1] - The total number of shares not subscribed in the rights issue amounts to 129 million shares [1] - The company has established a compensation arrangement through a placement agreement with a placement agent to facilitate the subscription of the unsubscribed shares [1] Group 2: Conditions and Outcomes - All conditions related to the rights issue and placement have been met, making the rights issue unconditional as of January 7, 2026 [1] - The total number of shares to be allotted and issued will be 297 million shares, which accounts for 100% of the shares offered in the rights issue [1]

Group 1 - The company announced a rights issue where shareholders will receive two (2) shares for every one (1) share held, with a total of 167,352,542 shares applied for, representing approximately 56.39% of the total shares offered [1] - The rights issue and placement became unconditional as all conditions outlined in the rights issue prospectus were met, with a total of 296,772,672 shares to be issued, accounting for 100% of the shares applied for [1] Group 2 - The total amount raised from the rights issue is approximately HKD 43.33 million, with a net amount of approximately HKD 40.75 million after expenses [2] - The net proceeds will be allocated as follows: approximately 14.72% (about HKD 6.00 million) for general working capital, 59.29% (about HKD 24.16 million) for repaying trade payables, 16.17% (about HKD 6.59 million) for investing in new projects to expand water business revenue, and 9.82% (about HKD 4.00 million) for maintenance and licensing in the mining business [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 本 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 本 公 司 證 券 的 邀 請 或 要 約。 誠 如 該 公 告 所 披 露，於2025年12月17日（星 期 三）下 午 四 時 正（即 最 後 接 納 時 限）， 本公司合共收取5份 有 效 申 請，涉 及 合 共167,352,542股 供 股 股 份，相 當 於 供 股 項 下提呈供股股份總數約56.39%。 基 於 上 述 有 效 接 納 及 申 請 結 果，補 償 安 排 涉 及 之 不 獲 認 購 供 股 股 份 總 數 為 129,420,130股 供 股 股 份。 本公司已根據上市規則第7.21(1)(b)條透過與配售代理訂立配售協議作出補償 安 排，據 此，本 公 司 有 條 件 委 任 配 售 代 理，而 配 售 代 理 有 條 件 同 意 擔 任 本 公 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00899 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 148,386,336 | | 0 | | 148,386,336 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 148,386,336 | | 0 | | 148,386,336 | 第 2 頁 共 10 頁 v 1.1.1 公司名稱: 中加國信控股股份有限公司（於百慕達註冊成立之有限公 ...